Form 4: Arrowhead COO Disposes of Shares, Gifts Stock

Arrowhead Pharmaceuticals COO Patrick O'Brien reported the disposition of common stock through gifts to relatives and sales under a 10b5-1 plan, including shares for tax withholding.

Summary

• Patrick O'Brien, Chief Operating Officer (COO) of Arrowhead Pharmaceuticals, Inc. (ARWR), reported transactions involving the disposition of common stock.
• On December 31, 2025, O'Brien gifted a total of 2,800 shares of common stock to relatives.
• On January 5, 2026, O'Brien sold a total of 49,493 shares of common stock.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan and included a partial disposition to satisfy tax withholding obligations.
• The shares were sold at weighted average prices ranging from $60.85 to $68.00 per share across multiple transactions.
• Following these transactions, O'Brien's beneficial ownership stands at 474,908 shares of Arrowhead Pharmaceuticals common stock, which includes shares underlying Restricted Stock Units subject to vesting.

Sentiment

Score: 5

Explanation: A Form 4 filing reports insider transactions, which are routine disclosures. The sales were conducted under a pre-arranged 10b5-1 plan, which mitigates the interpretation of negative sentiment, and some sales were for tax obligations. Gifts are also a neutral event.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an individual insider's equity transactions and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• Gifts of 2,800 shares of common stock were made to relatives on December 31, 2025.

Stakeholder Impact

• Shareholders may note the disposition of shares by a key executive, though sales under a 10b5-1 plan and for tax obligations are common and generally not indicative of a change in company outlook.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, COO, Patrick O'Brien, Equity Disposition, Tax Withholding